Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Unternehmen & Branche
| Name | Keros Therapeutics, Inc. |
|---|---|
| Ticker | KROS |
| CIK | 0001664710 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 423,1 Mio. USD |
| Beta | 0,99 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 243,864,000 | 87,014,000 | 2.30 | 338,021,000 | 303,132,000 |
| 2025-09-30 | 10-Q | 14,124,000 | -7,280,000 | -0.18 | 742,783,000 | 703,580,000 |
| 2025-06-30 | 10-Q | 18,168,000 | -30,696,000 | -0.76 | 757,165,000 | 706,734,000 |
| 2025-03-31 | 10-Q | 211,192,000 | 148,451,000 | 3.62 | 784,561,000 | 728,871,000 |
| 2024-12-31 | 10-K | 0 | -187,353,000 | -5.00 | 615,886,000 | 571,553,000 |
| 2024-09-30 | 10-Q | 0 | -52,956,000 | -1.41 | 579,271,000 | 532,835,000 |
| 2024-06-30 | 10-Q | 0 | -45,257,000 | -1.25 | 455,022,000 | 420,916,000 |
| 2024-03-31 | 10-Q | 0 | -43,114,000 | -1.21 | 485,819,000 | 453,947,000 |
| 2023-12-31 | 10-K | 151,000 | -152,992,000 | -5.20 | 370,025,000 | 332,213,000 |
| 2023-09-30 | 10-Q | 8,000 | -39,440,000 | -1.33 | 326,247,000 | 295,842,000 |
| 2023-06-30 | 10-Q | 0 | -37,505,000 | -1.27 | 356,306,000 | 326,260,000 |
| 2023-03-31 | 10-Q | 0 | -35,804,000 | -1.26 | 384,436,000 | 354,984,000 |
| 2022-12-31 | 10-K | 0 | -104,679,000 | -4.15 | 306,781,000 | 277,423,000 |
| 2022-09-30 | 10-Q | 0 | -23,509,000 | -0.92 | 252,550,000 | 241,025,000 |
| 2022-06-30 | 10-Q | 0 | -27,266,000 | -1.13 | 226,661,000 | 211,208,000 |
| 2022-03-31 | 10-Q | -24,186,000 | -1.01 | 235,142,000 | 223,494,000 | |
| 2021-12-31 | 10-K | 20,100,000 | -58,744,000 | -2.52 | 255,251,000 | 243,174,000 |
| 2021-09-30 | 10-Q | 0 | -20,297,000 | -0.87 | 229,962,000 | 218,478,000 |
| 2021-06-30 | 10-Q | 100,000 | -15,622,000 | -0.67 | 243,461,000 | 235,656,000 |
| 2021-03-31 | 10-Q | -15,885,000 | -0.68 | 257,730,000 | 248,372,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | BIENAIME JEAN JACQUES | Director | Open Market Purchase | 1,000 | 11.70 | 11,700.00 | +0,1% | |
| 2026-03-09 | BIENAIME JEAN JACQUES | Director | Open Market Purchase | 2,000 | 11.21 | 22,420.00 | +0,2% | |
| 2026-02-19 | Seehra Jasbir | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7,015 | 16.17 | -113,432.55 | -0,8% | |
| 2026-02-18 | Lerner Lorena Raquel | Officer, Chief Science Officer | Open Market Sale | -3,873 | 16.35 | -63,323.55 | -0,5% | |
| 2026-02-18 | Cho Esther | Officer, SVP, General Counsel | Open Market Sale | -4,745 | 16.35 | -77,580.75 | -0,6% | |
| 2026-02-18 | Regnante Keith | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -4,739 | 16.35 | -77,482.65 | -0,6% | |
| 2025-10-15 | ADAR1 Capital Management, LLC | 10% Owner | Open Market Sale | -254,669 | 17.75 | -4,520,374.75 | -32,5% | |
| 2025-10-15 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | Open Market Sale | -2,284,612 | 17.75 | -40,551,863.00 | -291,3% | |
| 2025-10-15 | ADAR1 Capital Management, LLC | 10% Owner | Open Market Sale | -743,358 | 17.75 | -13,194,604.50 | -94,8% | |
| 2025-10-15 | ADAR1 Capital Management, LLC | 10% Owner | Open Market Sale | -4,391,237 | 17.75 | -77,944,456.75 | -559,8% | |
| 2025-10-15 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | Open Market Sale | -155,262 | 17.75 | -2,755,900.50 | -19,8% | |
| 2025-10-15 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | Open Market Sale | -1,121,045 | 17.75 | -19,898,548.75 | -142,9% | |
| 2025-10-15 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | Open Market Sale | -1,226,412 | 17.75 | -21,768,813.00 | -156,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.